ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer

ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer

Background: The frequency of ROS1 rearrangement in non-small cell lung cancers has been reported from 1.6% to 2.3%. Materials and Methods: We examined 105 lung adenocarcinoma patients for ROS1 rearrangement which were negative for EGFR and anaplastic lymphoma kinase. Clinical characteristics of ROS1...

Full description

Bibliographic Details
Main Authors: Moushumi Suryavanshi, Manoj Kumar Panigrahi, Dushyant Kumar, Haristuti Verma, Mumtaz Saifi, Bharti Dabas, Ullas Batra, Dinesh Doval, Anurag Mehta
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2017-01-01
Series:Lung India
Subjects:
Anaplastic lymphoma kinase
crizotinib
EGFR
ROS1
Online Access:http://www.lungindia.com/article.asp?issn=0970-2113;year=2017;volume=34;issue=5;spage=411;epage=414;aulast=Suryavanshi

Internet

http://www.lungindia.com/article.asp?issn=0970-2113;year=2017;volume=34;issue=5;spage=411;epage=414;aulast=Suryavanshi

Similar Items